Descriptive epidemiology of hereditary angioedema emergency department visits in the United States, 2006-2007
- PMID: 22195693
- DOI: 10.2500/aap.2011.32.3478
Descriptive epidemiology of hereditary angioedema emergency department visits in the United States, 2006-2007
Abstract
Hereditary angioedema (HAE) is a rare inherited disorder of complement factor C1 inhibitor. In 2007 there were over 2000 HAE-related emergency department (ED) visits, nearly one-half of which culminated in a hospitalization. This study examines epidemiology and outcomes of hospital ED visits among HAE patients. We evaluated epidemiology, resource use, and discharge destinations of HAE (International Classification of Diseases, Version 9, clinical modification [ICD-9-CM] code 277.6) ED visits within the Nationwide Emergency Department Sample, part of Agency for Healthcare Research and Quality Healthcare Costs and Utilization Project, in 2006 and 2007. In 2006-2007, there were 5040 ED visits with HAE, of which 2705 (53.7%) had HAE as the principal diagnosis (HAE-PD). The mean age for all HAE visits was 38.2 years, and women accounted for 56.5% of all HAE visits. When HAE was not the primary reason for the visit, abdominal pain was the most prevalent (10%) presenting diagnosis. Two thousand fifty-nine (40.9%) resulted in a hospitalization. Although of all HAE ED visits that did not require a hospitalization, the vast majority was discharged routinely home, further care either at a skilled nursing facility or at home was required after 45 (0.9%) of all the HAE visits and 10 (0.4%) of the HAE-PD visits. Mean HAE ED visits costs were $1479 (95% confidence interval, $1028-1929). HAE ED visit volume is substantial. Although likely representing a fraction of the entire HAE population, prevention and acute treatment strategies aimed at those at risk for frequent exacerbations and disproportionate resource use need to be examined.
Similar articles
-
Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review.Orphanet J Rare Dis. 2024 Jul 8;19(1):256. doi: 10.1186/s13023-024-03265-z. Orphanet J Rare Dis. 2024. PMID: 38978028 Free PMC article. Review.
-
The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States, 2007.Allergy Asthma Proc. 2010 Nov-Dec;31(6):511-9. doi: 10.2500/aap.2010.31.3403. Epub 2010 Oct 20. Allergy Asthma Proc. 2010. PMID: 20964950
-
Descriptive epidemiology of hereditary angioedema hospitalizations in the United States, 2004-2007.Allergy Asthma Proc. 2011 May-Jun;32(3):248-54. doi: 10.2500/aap.2011.32.3452. Epub 2011 May 4. Allergy Asthma Proc. 2011. PMID: 21549036
-
Emergency Department Management of Hereditary Angioedema Attacks: Patient Perspectives.J Allergy Clin Immunol Pract. 2017 Jan-Feb;5(1):128-134.e4. doi: 10.1016/j.jaip.2016.06.029. Epub 2016 Sep 21. J Allergy Clin Immunol Pract. 2017. PMID: 27665386
-
Diagnosis and treatment of hereditary angioedema.Panminerva Med. 2012 Sep;54(3):241-53. Panminerva Med. 2012. PMID: 22801442 Review.
Cited by
-
Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review.Orphanet J Rare Dis. 2024 Jul 8;19(1):256. doi: 10.1186/s13023-024-03265-z. Orphanet J Rare Dis. 2024. PMID: 38978028 Free PMC article. Review.
-
Pathophysiology of bradykinin and histamine mediated angioedema.Front Allergy. 2023 Oct 18;4:1263432. doi: 10.3389/falgy.2023.1263432. eCollection 2023. Front Allergy. 2023. PMID: 37920409 Free PMC article. Review.
-
The prevalence of hereditary angioedema in a Chinese cohort with decreased complement 4 levels.World Allergy Organ J. 2021 Dec 18;15(1):100620. doi: 10.1016/j.waojou.2021.100620. eCollection 2022 Jan. World Allergy Organ J. 2021. PMID: 34992711 Free PMC article.
-
Leveraging unstructured data to identify hereditary angioedema patients in electronic medical records.Allergy Asthma Clin Immunol. 2021 Apr 20;17(1):41. doi: 10.1186/s13223-021-00541-6. Allergy Asthma Clin Immunol. 2021. PMID: 33879228 Free PMC article.
-
Hereditary angioedema patients would prefer newer-generation oral prophylaxis.J Drug Assess. 2021 Jan 6;10(1):51-56. doi: 10.1080/21556660.2020.1863699. J Drug Assess. 2021. PMID: 33489436 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
